Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects

• DOI: 10.1042/cs20030381
• Publication Date: 2004-07-27T09:32:03Z
• Authors: Morris J. BROWN; John COLTART; Kulasiri GUNEWARDENA; James M. RITTER; Timothy R. AUTON; James F. GLOVER
• Keywords: Plasma renin activity

Immunization against components of the renin–angiotensin system offers a potential alternative to daily medication in some patients with hypertension or heart failure. Our primary objective was determine whether sustained antibody titre Ang I (angiotensin I) can be achieved hypertensive patients. The secondary antibodies block renin system. Patients (n=27) essential responsive an ACEi (angiotensin-converting enzyme inhibitor) ARB blocker) were randomly assigned receive three four injections vaccine PMD3117 aluminium hydroxide (Alhydrogel™) over 6 week period. Antibody measured prior each injection and every 30 days until disappearance. Indices blockade changes aldosterone (blood urine) within-patient comparison pre- post-vaccination rise 24 h ambulatory blood pressure after 2 weeks withdrawal ARB. anti-(Ang rose from second both regimes peaked on day 64. Median half-life 85 (95% CI, 44 153) (where CI is confidence interval). Vaccination did not influence pressure, but significantly blunted fall plasma following At 42 first injection, excretion decreased by 1 31)% values receiving Alhydrogel™ (P=0.012). In hypertension, generated prolonged response I. Biochemical measurements show evidence system, higher titres will required achieve decrease pressure.